{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:27:30Z","timestamp":1772306850024,"version":"3.50.1"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":469,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Cancer"],"published-print":{"date-parts":[[2015,8,15]]},"DOI":"10.1002\/ijc.28965","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T13:27:40Z","timestamp":1399987660000},"page":"753-764","source":"Crossref","is-referenced-by-count":32,"title":["Bisphosphonates in breast cancer"],"prefix":"10.1002","volume":"137","author":[{"given":"Aju","family":"Mathew","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of Pittsburgh Cancer Institute; 5150 Center Avenue, UPMC Cancer Pavilion, Room 463 Pittsburgh PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Brufsky","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Pittsburgh Cancer Institute; 300 Halket Street, Room 3524 Pittsburgh PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"10.1002\/ijc.28965-BIB0001|ijc28965-cit-0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Poznak","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0002|ijc28965-cit-0002","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1002\/ijc.28965-BIB0003|ijc28965-cit-0003","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/ijc.28965-BIB0004|ijc28965-cit-0004","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","article-title":"Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro","volume":"98","author":"der Pluijm","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1002\/ijc.28965-BIB0005|ijc28965-cit-0005","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/ijc.28965-BIB0006|ijc28965-cit-0006","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/bcr2769","article-title":"Anti-tumour activity of bisphosphonates in preclinical models of breast cancer","volume":"12","author":"Holen","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1002\/ijc.28965-BIB0007|ijc28965-cit-0007","first-page":"75","article-title":"Decreased risk of breast cancer associated with oral bisphosphonate therapy","volume":"4","author":"Mathew","year":"2012","journal-title":"Breast Cancer"},{"key":"10.1002\/ijc.28965-BIB0008|ijc28965-cit-0008","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S1470-2045(11)70151-6","article-title":"Adjuvant bisphosphonates for early-stage breast cancer","volume":"12","author":"Brufsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1002\/ijc.28965-BIB0009|ijc28965-cit-0009","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1002\/ijc.28965-BIB0010|ijc28965-cit-0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1002\/ijc.28965-BIB0011|ijc28965-cit-0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1002\/ijc.28965-BIB0012|ijc28965-cit-0012","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11864-011-0163-3","article-title":"Bone targeted therapies in early breast cancer","volume":"12","author":"Tabane","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"10.1002\/ijc.28965-BIB0013|ijc28965-cit-0013","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1359\/jbmr.060118","article-title":"Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases","volume":"21","author":"Dunford","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1002\/ijc.28965-BIB0014|ijc28965-cit-0014","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"Suppl 4","key":"10.1002\/ijc.28965-BIB0015|ijc28965-cit-0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1002\/ijc.28965-BIB0016|ijc28965-cit-0016","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.28965-BIB0017|ijc28965-cit-0017","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1002\/ijc.28965-BIB0018|ijc28965-cit-0018","doi-asserted-by":"crossref","first-page":"232","DOI":"10.6004\/jnccn.2003.0022","article-title":"The role of bisphosphonates in breast cancer","volume":"1","author":"Theriault","year":"2003","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1002\/ijc.28965-BIB0019|ijc28965-cit-0019","first-page":"CD003474","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/ijc.28965-BIB0020|ijc28965-cit-0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0021|ijc28965-cit-0021","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"key":"10.1002\/ijc.28965-BIB0022|ijc28965-cit-0022","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/ijc.28965-BIB0023|ijc28965-cit-0023","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0024|ijc28965-cit-0024","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1002\/ijc.28965-BIB0025|ijc28965-cit-0025","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1002\/ijc.28965-BIB0026|ijc28965-cit-0026","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1002\/ijc.28965-BIB0027|ijc28965-cit-0027","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0028|ijc28965-cit-0028","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/ijc.28965-BIB0029|ijc28965-cit-0029","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1002\/ijc.28965-BIB0030|ijc28965-cit-0030","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1002\/ijc.28965-BIB0031|ijc28965-cit-0031","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/ijc.28965-BIB0032|ijc28965-cit-0032","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11912-008-0005-z","article-title":"Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors","volume":"10","author":"Brufsky","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"10.1002\/ijc.28965-BIB0033|ijc28965-cit-0033","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.2007-0152","article-title":"Cancer treatment-induced bone loss: pathophysiology and clinical perspectives","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1002\/ijc.28965-BIB0034|ijc28965-cit-0034","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0035|ijc28965-cit-0035","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0036|ijc28965-cit-0036","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1002\/ijc.28965-BIB0037|ijc28965-cit-0037","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2007.15.2967","article-title":"Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial","volume":"26","author":"Greenspan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0038|ijc28965-cit-0038","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"10.1002\/ijc.28965-BIB0039|ijc28965-cit-0039","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1002\/ijc.28965-BIB0040|ijc28965-cit-0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1002\/ijc.28965-BIB0041|ijc28965-cit-0041","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1200\/JCO.2009.24.5902","article-title":"Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial","volume":"28","author":"Poznak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0042|ijc28965-cit-0042","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1002\/ijc.28965-BIB0043|ijc28965-cit-0043","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial","volume":"12","author":"Llombart","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1002\/ijc.28965-BIB0044|ijc28965-cit-0044","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1002\/ijc.28965-BIB0045|ijc28965-cit-0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1002\/ijc.28965-BIB0046|ijc28965-cit-0046","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1002\/ijc.28965-BIB0047|ijc28965-cit-0047","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0048|ijc28965-cit-0048","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1002\/ijc.28965-BIB0049|ijc28965-cit-0049","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1002\/ijc.28965-BIB0050|ijc28965-cit-0050","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1002\/ijc.28965-BIB0051|ijc28965-cit-0051","article-title":"On Behalf of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG)'s Bisphosphonate Working Group","volume":"73","author":"Coleman","year":"2013","journal-title":"Cancer Res"},{"key":"10.1002\/ijc.28965-BIB0052|ijc28965-cit-0052","unstructured":"http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bone.pdf"},{"key":"10.1002\/ijc.28965-BIB0053|ijc28965-cit-0053","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","article-title":"A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics","volume":"29","author":"Pazianas","year":"2007","journal-title":"Clin Ther"},{"key":"10.1002\/ijc.28965-BIB0054|ijc28965-cit-0054","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1002\/ijc.28965-BIB0055|ijc28965-cit-0055","first-page":"504","article-title":"Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study","volume":"19","author":"Brufsky","year":"2013","journal-title":"Breast J"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.28965","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/ijc.28965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T16:16:52Z","timestamp":1625156212000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.28965"}},"subtitle":["Bisphosphonates in breast cancer"],"short-title":[],"issued":{"date-parts":[[2014,5,20]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8,15]]}},"URL":"https:\/\/doi.org\/10.1002\/ijc.28965","relation":{},"ISSN":["0020-7136"],"issn-type":[{"value":"0020-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5,20]]}}}